The Coalition for Epidemic Preparedness Innovations (CEPI) is to invest up to $54.3 million to support a pivotal Phase III clinical trial that aims to help advance Moderna’s investigational mRNA-based H5 pandemic influenza vaccine candidate, mRNA-1018, to licensure. The organisation says the funding marks a significant step forward in global pandemic preparedness that could enable […]
To read this content in full, you need to login.
Not yet a DDW member? Join now for FREE – it takes less than 2 minutes!